Enliven Therapeutics (ELVN) Stock Forecast, Price Target & Predictions
ELVN Stock Forecast
Enliven Therapeutics stock forecast is as follows: an average price target of $33.00 (represents a 47.85% upside from ELVN’s last price of $22.32) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
ELVN Price Target
The average price target for Enliven Therapeutics (ELVN) is $33.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $34.00 to $32.00. This represents a potential 47.85% upside from ELVN's last price of $22.32.
ELVN Analyst Ratings
According to 3 Wall Street analysts, Enliven Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ELVN stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Enliven Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 10, 2024 | Colleen Kusy | Robert W. Baird | $32.00 | $22.58 | 41.72% | 43.37% |
| Apr 09, 2024 | Salim Syed | Mizuho Securities | $34.00 | $18.30 | 85.79% | 52.33% |
The latest Enliven Therapeutics stock forecast, released on Jun 10, 2024 by Colleen Kusy from Robert W. Baird, set a price target of $32.00, which represents a 41.72% increase from the stock price at the time of the forecast ($22.58), and a 43.37% increase from ELVN last price ($22.32).
Enliven Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $33.00 |
| Last Closing Price | $22.32 | $22.32 | $22.32 |
| Upside/Downside | -100.00% | -100.00% | 47.85% |
In the current month, the average price target of Enliven Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Enliven Therapeutics's last price of $22.32. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 09, 2024 | H.C. Wainwright | - | Buy | Initialise |
| Aug 14, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Apr 25, 2022 | SVB Leerink | Market Perform | Market Perform | Hold |
Enliven Therapeutics's last stock rating was published by H.C. Wainwright on Sep 09, 2024. The company Initialise its ELVN rating from "null" to "Buy".
Enliven Therapeutics Financial Forecast
Enliven Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Enliven Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ELVN's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Enliven Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict ELVN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Enliven Therapeutics's previous annual EBITDA (undefined) of $NaN.
Enliven Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-28.85M | $-27.88M | $-28.85M | $-27.40M | $-25.55M | $-24.31M | $-26.44M |
| High Forecast | $-28.85M | $-27.88M | $-28.85M | $-27.40M | $-25.55M | $-21.51M | $-26.44M |
| Low Forecast | $-28.85M | $-27.88M | $-28.85M | $-27.40M | $-25.55M | $-25.71M | $-26.44M |
| Surprise % | - | - | - | - | - | - | - |
Enliven Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ELVN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Enliven Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Enliven Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ELVN last annual SG&A of $NaN (undefined).
Enliven Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.60 | $-0.58 | $-0.60 | $-0.57 | $-0.53 | $-0.51 | $-0.55 |
| High Forecast | $-0.60 | $-0.58 | $-0.60 | $-0.57 | $-0.53 | $-0.45 | $-0.55 |
| Low Forecast | $-0.60 | $-0.58 | $-0.60 | $-0.57 | $-0.53 | $-0.53 | $-0.55 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Enliven Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ELVN previous annual EPS of $NaN (undefined).
Enliven Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.51 | $24.75 | 1539.07% | Buy |
| IMRX | Immuneering | $2.02 | $17.50 | 766.34% | Buy |
| KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
| AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
| GOSS | Gossamer Bio | $0.92 | $3.75 | 307.61% | Buy |
| REPL | Replimune Group | $11.13 | $24.20 | 117.43% | Buy |
| GPCR | Structure Therapeutics | $40.84 | $86.00 | 110.58% | Buy |
| CELC | Celcuity | $14.98 | $31.50 | 110.28% | Buy |
| LYRA | Lyra Therapeutics | $0.28 | $0.50 | 78.57% | Hold |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| MLTX | MoonLake Immunotherapeutics | $51.14 | $79.33 | 55.12% | Buy |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
| ELVN | Enliven Therapeutics | $22.32 | $33.00 | 47.85% | Buy |
ELVN Forecast FAQ
Is Enliven Therapeutics a good buy?
Yes, according to 3 Wall Street analysts, Enliven Therapeutics (ELVN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of ELVN's total ratings.
What is ELVN's price target?
Enliven Therapeutics (ELVN) average price target is $33 with a range of $32 to $34, implying a 47.85% from its last price of $22.32. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Enliven Therapeutics stock go up soon?
According to Wall Street analysts' prediction for ELVN stock, the company can go up by 47.85% (from the last price of $22.32 to the average price target of $33), up by 52.33% based on the highest stock price target, and up by 43.37% based on the lowest stock price target.
Can Enliven Therapeutics stock reach $30?
ELVN's average twelve months analyst stock price target of $33 supports the claim that Enliven Therapeutics can reach $30 in the near future.
What are Enliven Therapeutics's analysts' financial forecasts?
Enliven Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-76.302M (high $-73.497M, low $-77.705M), average SG&A $0 (high $0, low $0), and average EPS is $-1.587 (high $-1.529, low $-1.616). ELVN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-113M (high $-113M, low $-113M), average SG&A $0 (high $0, low $0), and average EPS is $-2.35 (high $-2.35, low $-2.35).